A spinout company from the Zhang group with close connection to Northeastern University, the driving these of pacDNA LLC is greatly to expand on the areas of disease for which an oligonucleotide-based therapy can be developed. The firm's proprietary delivery technology - designated the Brushield™ - is structured to boost biodistribution in otherwise hard-to-deliver sites, reducing potential side effects, and generating lasting potency - making possible the development of multiple therapies for diseases that are currently out of reach.
